Although the prostate-specific antigen (PSA) has been used extensively as a PCa screening tool, its usage as a serum marker has drawbacks, such as an inability to accurately distinguish between benign and malignant conditions [8]. The gene discussed is KLK3; the disease is posterior cortical atrophy.